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Abstract Candida glabrata is one of most prevalent
yeast in fungal infections, especially in immunocom-
promised patients. Its azole resistance results in a low
therapeutic response, particularly when associated
with biofilms. The main goal of this work was to study
the effectiveness of voriconazole (Vcz) against C.
glabrata biofilms oral pathologies, as esophageal or
oropharyngeal candidiasis. Antifungal susceptibilities
were determined in pre-formed 24-h-biofilms and
ERG genes expression was determined by qRT-PCR.
Protein quantification was performed using BCAKit,
carbohydrate was estimated according to the Dubois
assay and b-1,3 glucans concentration were deter-
mined using Glucatell kit. Finally, ergosterol, Vcz,
and fluconazole (Flu) concentrations within the bio-
film matrices were determined by RP-HPLC. Results
showed that C. glabrata biofilms were more suscep-
tible to Vcz than to Flu and that ERG genes expression
evidenced an overexpression of the three ERG genes
in the presence of both azoles. The matrix content
presented a remarked decrease in proteins and an
increase in carbohydrates, namely b-1,3 glucans.
Ergosterol was successfully detected and quantified
in the biofilm matrices, with no differences in all the
considered conditions. Vcz demonstrated better dif-
fusion through the biofilms and better cell penetration
capacities, than Flu, indicating that the structure of the
drug molecule fully influences its dissemination
through the biofilm matrices. This work showed that
Vcz is notably more effective than Flu for the
treatment of resistant C. glabrata oral biofilms, which
demonstrates a clinical relevance in its future use for
the treatment of oropharyngeal/esophageal candidiasis
caused by this species.
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Introduction
The occurrence of fungal infections, as candidiasis and
candidemia, has been increasing significantly in the last
decades, contributing to high morbidity and mortality.
The enhanced use of broad-spectrum antibiotics,
catheters and parenteral nutrition, the growth in the
number of immunosuppressive diseases, the disruption
of mucosal barriers, and the increase in chemotherapy
and radiotherapy, are all important risk factors for the
development of candidemia [1, 2]. Candida species
belong to the normal microbiota of the individual’s oral
cavity, gastrointestinal, urinary, and vaginal tracts [2]
and are responsible for numerous clinicalmanifestations
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frommucocutaneous overgrowth to bloodstream severe
infections [1]. Candida albicans is the predominant
species in both health and disease conditions, yet, in the
last two decades the number of infections due to non-
Candida albicans Candida (NCAC) species increased
significantly, particularly those involving Candida
glabrata. This species lacks some of the virulence
factors allied to Candida pathogenicity, such as hyphal
growthor secret hydrolases [3], but it does not turn out to
be less virulent [4, 5]. Oropharyngeal/esophageal can-
didiasis are serious oral diseases characterized by white
patches or plaques (biofilms of Candida) on the tongue
and other oral mucous membranes. These infections are
usual among immunosuppressed adults, but can also be
seen rarely in immunocompetent individuals [6–9].
The ability to form biofilm is one of the most
important concerns in Candida pathogenicity. Biofilm
production can occur on the host mucosa (e.g., mouth,
esophagus) and on the surface of medical indwelling
devices, involving a matrix that encloses yeasts’
micro-colonies in a complex structure [4]. The anti-
fungal biofilm resistance can be inducible in reaction
to a drug, or a permanent genetic change resulting
from prolonged exposure to that drug. Systematically,
this phenomenon comprises changes or overexpres-
sion of the spot molecules, active extrusion through
efflux pumps, limited diffusion, tolerance, which are
all characterized mechanisms used by Candida to
combat the antifungal treatment effects [4, 5].
Candida glabrata infections are characterized by
an intrinsic low susceptibility to azoles, including the
imidazoles (e.g., miconazole) and triazoles (e.g.,
fluconazole, voriconazole) [10, 11]. Voriconazole
(Vcz) is a second-generation antifungal agent, which
fortunately, presently shows a better Candida suscep-
tibility [12–14]. This compound has shown to be a
good alternative to treat candidiasis [15–19], in
opposition to fluconazole (Flu), which has been
largely used for decades, as a prophylactic or thera-
peutic treatment, inducing drug resistance mecha-
nisms in Candida [10, 20].
The 2016’s guidelines for esophageal and oropha-
ryngeal candidiasis and patients having fluconazole-
refractory disease recommend the use of voriconazole
(‘‘strong recommendation; high-quality evidence’’)
[21]. Therefore, this work expects to elucidate the
efficacy of Vcz in the treatment of these biofilm
pathologies, specifically involving Candida glabrata,
the most azole-resistant NCAC. It also aims at an
evaluation of the response regarding the genes
expression and matrix composition after a contact
with this drug.
Methods
Organisms
Two clinical isolates of C. glabrata recovered from
vaginal (C. glabrata 534784) and urinary (C. glabrata
562123) tracts, from Hospital Escala Braga in Portu-
gal, and one reference strain from the American Type
Culture Collection (C. glabrata ATCC2001) were
used in the course of this study. The identity of all
isolates was confirmed using CHROMagar Candida
(CHROMagar, Paris, France) and by PCR-based
sequencing using specific primers (ITS1 and ITS4)
against the 5.8 s subunit gene Ref. [22]. Genomic
DNA was extracted following previously described
procedures [23]. The PCR products were sequenced
using the ABI-PRISM Big Dye terminator cycle
sequencing kit (Perkin Elmer, Applied Biosystems,
Warrington, UK).
Growth Conditions
For each experiment, strains were subcultured on
Sabouraud dextrose agar (SDA) (Merck, Darmstadt,
Germany) for 24 h at 37 C. Cells were then inoculated
in Sabouraud dextrose broth (SDB) (Merck, Darmstadt,
Germany) and incubated for 18 h at 37 C under
agitation at 120 rpm. After incubation, the cells were
harvested by centrifugation at 3000g for 10 min at 4 C
andwashed twice with phosphate-buffered saline (PBS,
pH = 7.5). Pellets were then suspended in RPMI or
SDA, and the cellular density was adjusted to 1 9 105
cells/mL, using a Neubauer counting chamber.
Antifungal Drugs
Vcz and Flu were kindly provided by Pfizer, S.A. in
its pure compound. Aliquots of 5000 mg/L were
prepared using dimethyl-sulfoxide (DMSO). The final
concentrations used were prepared with RPMI 1640
(Sigma-Aldrich, Roswell Park) or SDB medium and
were: 10, 100, and 1000 mg/L for both drugs.
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Biofilm Susceptibility
Standardized cell suspensions (200 lL) were placed
into selected wells of 96-well polystyrene microtiter
plates (Orange Scientific, Braine-l‘Alleud, Belgium).
RPMI 1640 was used without cells and antifungal
agent, as a negative control. As positive control, only
cell suspensions were tested without antifungal agent.
At 24 h, 100 lL of RPMI 1640 was removed and an
equal volume of fresh RPMI 1640 plus the respective
antifungal concentration were added (2 9 concen-
trated). The plates were incubated at 37 C for more
24 h, a total of 48 h at 120 rpm.
The number of cultivable cells on biofilms was
determined by the enumeration of colony forming
units (CFUs) [23]. For that, after the period of
biofilm formation, all medium was aspired and the
biofilms washed once with 200 lL of PBS to
remove non-adherent cells. Then, biofilms were
scraped from the wells and the suspensions were
vigorously vortexed for 2 min to disaggregate cells
from the matrix.
Effect of Vcz and Flu on Biofilm Matrix
Extraction Method
For matrix analysis, biofilms were formed in 24-well
polystyrene microtiter plates (Orange Scientific,
Braine-l’Alleud, Belgium) [23]. For this, 1000 lL of
yeast cell suspension (1 9 105 cells/mL in SDB or
SDB with Vcz or Flu at 10 and 1000 mg/L) were
added to each well and the biofilms performed as
described previously. After 24 h, 500 lL of SDB
medium was removed and an equal volume of fresh
SDB with or without the antifungal agents was added.
After 48 h, biofilms were scraped from the 24-well
plates, resuspended in ultra-pure water, sonicated
(Ultrasonic Processor, Cole-Parmer, Illinois, USA) for
30 s at 30 W, and then the suspension vortexed for
2 min. The suspension was centrifuged at 5000g for
5 min at 4 C and the supernatant filtered through a
0.2 lm nitrocellulose filter. The pellets were dried at
37 C until a constant dry biofilm weight was
determined.
Protein Determination
The protein content of the biofilm matrix was
measured using the BCA Kit (bicinchoninic acid,
Sigma-Aldrich, St Louis, USA), using bovine serum
albumin as a standard. The values were normalized per
g of dry weight of biofilm and presented as mg of
protein/g of dry weight of biofilm.
Carbohydrate Determination
Total carbohydrate content of the biofilm matrix was
estimated according to theprocedureofDubois et al. [24],
using glucose as standard. The values were normalized
pergofdryweight biofilmand thevaluespresented asmg
of carbohydrate/g of dry weight of biofilm.
b-1,3 Glucans Concentration Determination
The b-1,3 glucans concentrations were determined
using Glucatell kit (Cape Cod, East Falmouth, USA).
The values were normalized per pg/mL of b-1,3
glucans and per total of carbohydrates content.
Ergosterol Determination
For the ergosterol extraction, 2.0 mL of n-hexan (Fisher
Chemicals) was added to 10.0 mL of the matrix
suspension prepared as previously described and then
submitted to vortex during 1 min. This procedure was
performed three times and the top solution sequestered
to a 10.0 mL amber bottle. After the extraction, the
solutions were dried with nitrogen until all the organic
solvent evaporated. The dried extract was resuspended
in 2.0 mL of methanol (Fisher Chemicals), filtered with
a 0.45 lm filter, and stored at-20 C [25].
The high-pressure liquid chromatography
(HPLC—Varian 9002/Pro-Star) method was per-
formed using a C18 column (YMC, Inc.). An isocratic
mobile phase of 100% of methanol (Fisher Chemicals)
with a flow of 1 mL/min, during 20 min was used for
each sample quantification. The results were automat-
ically revealed by the HPLC detector and then
normalized by g of dry weight biofilm determined
for each strain and condition [25].
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Gene Expression Analysis
Gene Selection and Primer Design for Quantitative
Real-Time PCR
Three genes (ERG3, ERG6, and ERG11) were selected
to study their expression in biofilm cells in the absence
and presence of both drugs. The gene sequences of
interest were obtained from Candida Genome Data-
base and the primers for quantitative real-time PCR
(qRT-PCR) were designed using Primer 3 (http://
primer3.ut.ee/) Web-based software and are listed in
Table 1. ACT1 was chosen to be the housekeeping
gene. In order to verify the specificity of each primer
pair for its corresponding target gene, PCR products
were first amplified from C. glabrata ATCC2001.
Preparation of Biofilm Cells for RNA Extraction
Biofilms of the three strains were grown in 24-well
microtiter plates (Orange Scientific, Braine-l’Alleud,
Belgium) in three different conditions—0 (control), 10
and 1000 mg/L of Vcz or Flu—with a final concen-
tration of 1 9 105 cells/mL, as described above. After
biofilm formation, the medium was aspired and the
wells were washed with PBS to remove non-adherent
cells. The biofilms were scraped fromwells with 1 mL
of PBS and sonicated (Ultrasonic Processor, Cole-
Parmer, Illinois, USA) for 30 s at 30 W to separate the
cells from the biofilm matrix. Cells were harvested by
centrifugation at 5000 g for 5 min at 4 C.
RNA Extraction
RNA extraction was performed using PureLink RNA
Mini Kit (Invitrogen, Carlsbad, USA). Prior to RNA
extraction, a lysis buffer (PureLink RNAMini kit) was
prepared adding 1% of b-mercaptoethanol. Then,
500 lL of lysis buffer and glass beads (0.5 mm
diameter) were added to each pellet. These mixes were
homogenized twice for 30 s using a Mini-BeadBeater
8 (Stratech Scientific, Soham, UK). After cell disrup-
tion, the PureLink RNA Mini Kit (Invitrogen, Carls-
bad, USA) was used for total RNA extraction
according to the manufacturer’s recommended proto-
col. To avoid potential DNA contamination samples
were treated with RNase-Free I (Invitrogen, Carlsbad,
USA).
Synthesis of cDNA
To synthesize the complementary DNA (cDNA) the
iScript cDNA Synthesis Kit (Bio-Rad, Berkeley,
USA) was used according to the manufacturer’s
instructions. For each sample 10 lL of the extracted
RNA was used at a final reaction volume of 50 lL.
cDNA synthesis was performed firstly at 70 C for
5 min and then at 42 C for 1 h. The reaction was
stopped by heating for 5 min at 95 C.
Quantitative Real-Time PCR (qRT-PCR)
Real-time PCR (CFX96 Real-Time PCR System; Bio-
Rad, Berkeley, USA) was used to determine the
relative levels of ERG3, ERG6, and ERG11 mRNA
transcripts in the RNA samples, with ACT1 used as a
reference for Candida housekeeping gene. Each
reaction mixture consisted of a working concentration
of SoFast EvaGreen Supermix (Bio-Rad, Berkeley,
USA), 50 lM forward and reverse primers, and 4 lL
cDNA, in a final reaction volume of 20 lL. Negative
controls (water), as well as, non-transcriptase reverse
controls (NRT) were included in each run. The relative
Table 1 Primers and
targets used for the gene
expression analysis
Sequence (50 ? 30) Primer Target
50-CAC CCA GTC GGT TAC TT-30 Forward ERG3
50-TTG ACA ACT GGG TTG GA-30 Reverse
50-CTT CGA CAA AGT GTA CGC GA-30 Forward ERG6
50-TAA ACG GCG AAA GTA CCA-30 Reverse
50-CTC CAT ACT TGC CAT TCG-30 Forward ERG11
50-CTT CAG TTG GGT AAC GCC AT-30 Reverse
50-GTT GAC CGA GGC TCC AAT GA-30 Forward ACT1
50-CAC CGT CAC CAG AGT CCA AA-30 Reverse
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quantification of each gene expression was performed
by the Pfaffl method [26].
Diffusion of Vcz and Flu Through the Biofilm
Matrices
Sample Treatment
Biofilm was prepared as explained before, using a
total volume of 500 lL. At 24 h, 250 lL were
removed and an equal volume of fresh SDB plus the
respective antifungal concentration (2 9 concen-
trated) was added. The plates were incubated at
37 C for more 24 h at 120 rpm. After 48 h, first, all
medium was collected (approximately 350 lL), cen-
trifuged at 12,000 rpm during 10 min, and filtered
with a 0.45 lm filter. Then, 150 lL of sterile water
was applied above the biofilm, for scraping it. The
suspension was collected, sonicated during 10 s at
30 W, centrifuged at 12,000 rpm during 10 min, and
finally filtered with a 0.45 lm filter. The samples were
stored at -20 C until the high-pressure liquid chro-
matography (HPLC) analysis [27].
Reverse-Phase High-Pressure Liquid
Chromatography
The HPLC (HPLC—Varian 9002/Pro-Star) method
was performed using a C18 column (YMC, Inc.) in a
Varian 9002/Pro-Star equipment. An isocratic mobile
phase was used for both drugs.
For Vcz, a slightly modified method from Ibrahim
et al. [28] was used. The mobile phase was 0.05 M
disodium hydrogen phosphate buffer (pH 5.5)/ace-
tonitrile (1:1, v/v) (Fisher Chemicals) with a flow of
1 mL/min, during 10 min for each sample. The
retention time was 7.5 min, at 255 nm.
For Flu, a slightly modified method from Shastri
et al. [29] was used. The mobile phase was acetoni-
trile/water (50:50) (Fisher Chemicals) with a flow of
1 mL/min, during 6 min for each sample. The reten-
tion time was 3.5 min, at 260 nm.
As the diffusion procedure was developed and
optimized by the group [27], all the controls and
calibration curves were performed in order to guaran-
tee its applicability.
The results were normalized by g of dry weight
biofilm determined for each strain and condition.
All the described experiments were performed in
triplicate and in three independent assays.
Statistical Analysis
Results were compared using one-way ANOVA and
Dunnett’s multiple comparisons test, using GraphPad
Prism 5 software. All tests were performed with a
confidence level of 95%.
Results
In order to determine the susceptibility of C. glabrata
biofilms to Vcz, biofilms were developed during 24 h
and then incubated for more 24 h in the presence of
different concentrations of Vcz and Flu (control).
Table 2 shows the percentage of cell death (biofilm
cell viability) of eachC. glabrata strain, when biofilms
were exposed to 10, 100 and 1000 mg/L of Vcz and
Flu concentrations. After a 10 or 100 mg/L treatment
with the drugs, neither strains accomplished a reduc-
tion of, at least, 50%. On contrary, using 1000 mg/L of
Vcz, C. glabrata 562123 reached a very good biofilm
cell reduction of 70.57%, whereas C. glabrata
ATCC2001 and C. glabrata 534784 reached 57.32%
and 43.37% respectively. As expected, a different
behavior occurred with Flu for all strains: this drug
was unable to eradicate C. glabrata’s viable biofilm
cells, even using the higher concentration (1000 mg/
Table 2 Percentage of cell death found in biofilms of C.
glabrata strains treated with different concentrations of
voriconazole in comparison with cells exposed to fluconazole
C. glabrata strain [Drugs] mg/L % Biofilm cell death
Vcz Flu
ATCC2001 10 0.62 0.75
100 1.71 2.34
1000 57.32 2.22
562123 10 0 0
100 0 0
1000 70.57 2.18
534784 10 0 3.54
100 0 4.62
1000 43.37 5.56
Bold: cell death higher than 50%
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L) (Table 2). In fact, the higher reduction was noticed
for C. glabrata 534784, merely 5.56%. This condition
highlights the pronounced difference between a sec-
ond-generation azole (Vcz) and a long-standing azole
(Flu).
As it is well known, oral biofilms resistance to
antifungal agents can be due to both cell genetic
alterations and the presence of the biofilm matrix.
Therefore, an evaluation of the influence of both
agents in the expression of the genes (ERG) involved
in the biosynthesis of ergosterol (the target of azoles),
a well-known mechanism of azoles’ resistance was
ensuing performed [30, 31] and results are shown in
Fig. 1. In general, the results demonstrate that theERG
gene expression levels are gene, strain, dose and
azoles’ molecule dependent, with significant differ-
ences (P\ 0.05, P\ 0.001 and P\ 0.0001). C.
glabrata ATCC2001, showed a visible lower n-fold
expression for all ERG genes (Fig. 1) compared to the
two isolate strains.
Regarding the study of the biofilm matrix compo-
sition and according to the previous results, C.
glabrata’s biofilms were treated with 10 and
1000 mg/L of Vcz and then compared with the control
(Flu). In order to obtain additional insights into the
causes of the increase of C. glabrata’s oral biofilms
resistance to azoles and the differences found between
the two agents, the biofilm matrices were analyzed in
terms of the most important compounds, namely total
carbohydrates, b-1,3 glucans, proteins, and ergosterol
(Fig. 2; Tables 2, 3).
Notably, a decrease was observed in protein
quantities with an increase in the amount of carbohy-
drates, in the presence of both azoles. This pattern was
specially noted for C. glabrata 562123 (Fig. 2).
Overall, the quantity of carbohydrates in the presence
of Vcz was a bit lower than in presence of Flu for the
three strains. The quantification of proteins in biofilm
matrices (Fig. 2) showed a significant decrease in
biofilms grown with Vcz and Flu. The higher effect
was observed for C. glabrata ATCC2001, with Flu
application, and the lower effect for C. glabrata
534784, for both drugs. This effect was more percep-
tible for biofilms grown with Flu, especially for the
lower concentration of antifungal agent tested (10 mg/
L). Concerning the quantification of total b-1,3
glucans, the results confirm that, in general, there
was an increase of total b-1,3 glucans per total
carbohydrates, consistent with the previously
observed rise of carbohydrates concentration.
Afterwards, the detection and quantification of
ergosterol in biofilms matrices were carried out. This
lipid was effectively detected but no alterations on its
amount noticed in the matrices exposed to both
agents (Table 4). For a final approach, the quantity of
the azole agents present in the biofilm matrix and the
consequent amount of drug capable of reaching the
cells were also evaluated. A concentration of
1000 mg/L of each azole was applied in a 24-h-
biofilm for an additional 24 h. Then, the quantity
diffused within the biofilm and/or absorbed by the
cells was determined according to a protocol
described for Flu [27]. Interestingly, the results
indicate that Vcz had a higher capacity to penetrate
the biofilm net, reaching and eliminating the cells. As
it can be observed in Table 4, Flu was not so effective
in all these processes, which may explain its inability
to reduce C. glabrata’s oral biofilms, on contrary to
the good therapeutic response that Vcz has shown
(Table 4).
Discussion
Among the Candida species, C. glabrata is the
second most prevalent pathogen in humans in the
USA and the third in Europe, after C. albicans and C.
parapsilosis [32, 33]. Candida species developed the
capability to adapt to different niches and to invade
quite a lot of epithelia, namely esophagus, orophar-
ynx or, in even more serious cases, causing sep-
ticemia. These infections are very difficult to treat
with the traditional antifungal therapies and, conse-
quently, have a high reported morbidity and mortality
[34–38].
Agents within the azole class, like Vcz and Flu, are
able to vary decisively affecting the spectrum of
activity, their pharmacokinetic profiles, and toxicities.
Vcz and Flu are triazolic derivatives, resulting from
replacement of the imidazole ring by triazole, which
favors a broad spectrum of action and selectivity for
cytochrome P450 fungal cell.Candida glabrata grows
only as yeast form in vivo, and it is believed that the
increasing of C. glabrata infections is due to its
intrinsically low susceptibility to azoles (e.g. Flu)
[39–41].
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Therefore, the main purposes of this work were to
evaluate if Vcz is a good choice to treat, specifically,
C. glabrata´s oral biofilms infections, as well to
elucidate the mechanisms behind its different
responses. Due to its recurrent and traditional use,
Flu was used as a control during this study.
Fig. 1 ERG3, ERG6, and
ERG11 n-fold expressions
in biofilm cells for each
strain, with different
concentrations of
voriconazole and
fluconazole (*P\ 0.05;
**P\ 0.001;
***P\ 0.0001)
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Regarding the susceptibility tests of C. glabrata’s
biofilms, results show that the two lower concentra-
tions (10 and 100 mg/L) were not effective for the
reduction of a minimum of 50% of the biofilm for both
drugs. The same happened with 1000 mg/L of Flu. In
opposition, with 1000 mg/L of Vcz, this reduction was
easily reached, noticeably for C. glabrata 562123
which had the highest decrease (70.57%). These
evidences corroborate the reported facts that (oral)
biofilm cells are much more resistant to antifungal
agents than planktonic cells [42–47] and are particu-
larly resistant to azoles [48–50].
The relation between the role of the ERG3, ERG6,
and ERG11 expression with the Vcz biofilm’s cells
susceptibility was evaluated in C. glabrata’s biofilm
grown in the presence of Vcz or Flu, by qRT-PCR
Fig. 2 Content of
carbohydrates and proteins
content in biofilm matrices
of Candida glabrata strains
treated with different
concentrations of
voriconazole (A) and
fluconazole (B) (*P\ 0.05;
**P\ 0.001;
***P\ 0.0001)
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(Fig. 1). ERG3, the gene responsible for the conver-
sion of ergosta-5, 7, 24 (28)-trienol to episterol [51],
showed an inferior expression for all strains in the
presence of Vcz and Flu. ERG6, linked to the
transformation of fecosterol to zymosterol and
ERG11, the gene in charge of the production of
lanosterol from ignosterol (ergosterol biosynthesis),
presented the greater expression in both azoles,
remarkably for the isolate strains (C. glabrata
562123 and C. glabrata 534784). This event occurred
probably due to the interference of the azole drugs
with the 14a-lanosterol demethylase, obstructing its
pathway to produce ergosterol, failing to repose this
lipid in the cell membrane [51]. In general, the
response was higher for lower concentrations of both
drugs (10 mg/L). This assertive reaction to the pres-
ence of Vcz and Flu shows the high ability of C.
glabrata to rapidly adapt to stress, as it has been
showed before [52–55], but does not fully explain the
response of C. glabrata cells when Vcz is used (and
comparing with Flu) in clinical therapeutics. So, the
absence of a clear correlation between ERG genes
expression and the susceptibilities profiles led us to
explore the role of the biofilm matrix in azole
resistance.
Figure 2 shows a solid decrease in the protein
quantification in the presence of both azoles, espe-
cially for C. glabrata ATCC2001, with the use of Flu
(and mostly in the lower concentration used), a
phenomenon that may be explained by a response in
the stress induced by the drug [56]. On the other side,
both drugs instigated a minor effect in the loss of
proteins, for C. glabrata 534784. On the contrary,
biofilms developed with Vcz or Flu displayed an
increase in the amount of carbohydrates (Fig. 2),
increase that was also confirmed in the quantification
of b-1,3 glucans (Table 3). b-1,3 glucans are found in
cell wall of Candida species and also in the biofilm
Table 3 b-1,3 glucans/carbohydrates ratio and ergosterol concentration on biofilm matrices of Candida glabrata strains in the
presence of voriconazole and fluconazole
C. glabrata strain [Drug] mg/L [b-1,3 glucans]/carbo
hydrates ratio
Vcz
[b-1,3 glucans]/car
bohydrates ratio
Flu
[Ergosterol] mg/g
biofilm ± SD
Vcz
[Ergosterol] mg/g
biofilm ± SD
Flu
ATCC2001 0 1.2 9 10-4 1.17 ± 0.70
10 1.8 9 10-4 9.8 9 10-4 0.58 ± 0.21 1.15 ± 0.77
1000 1.1 9 10-4 7.4 9 10-4 0.79 ± 0.16 0.51 ± 0.14
562123 0 1.3 9 10-4 1.48 ± 0.71
10 1.7 9 10-4 8.8 9 10-4 0.95 ± 0.47 1.01 ± 0.09
1000 9.0 9 10-5 4.3 9 10-4 1.45 ± 0.30 1.39 ± 0.25
534784 0 1.2 9 10-4 1.32 ± 0.67
10 2.7 9 10-4 11.4 9 10-4 1.04 ± 0.21 0.75 ± 0.05
1000 1.7 9 10-4 7.5 9 10-4 2.16 ± 1.01 1.45 ± 0.07
SD standard deviation
Table 4 Antifungal drug diffusion through Candida glabrata biofilm matrices and supernatant
Drug C. glabrata strain [Drug] matrix
(mg/L) ± SD
[Drug] supernatant
(mg/L) ± SD
Voriconazole ATCC2001 0.44 ± 0.20 5.38 ± 1.20
562123 0.43 ± 0.21 5.27 ± 1.38
534784 0.60 ± 0.25 5.85 ± 1.67
Fluconazole ATCC2001 670.80 ± 61.87 69.21 ± 21.49
562123 551.87 ± 56.31 60.81 ± 20.10
534784 702.29 ± 77.92 69.88 ± 17.06
SD standard deviation
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matrix, being linked to the antifungal resistance, by
making it difficult to the drugs to diffuse through the
biofilm matrices and reach the yeast cells [57–59].
This change in the biofilm matrix composition may be
an effort of the cells to obtain a denser matrix,
inflexible and more protective for their environment
with these biopolymers. Thus, for the obtained results,
it is likely that C. glabrata’s biofilm cells are
attempting to respond to the azole-caused-stress,
producing as many polymers of carbohydrates as
possible, aiming to thick the biofilm matrix and, thus,
protecting the cells against the drugs.
Additionally, it was questioned whether ergosterol,
which is a specificCandida cell membrane lipid, could
be an important factor in the antifungal resistance orC.
glabrata’s oral biofilm infections. The results showed
that this lipid could not be associated with the
resistance or tolerance mechanisms, since, generally,
there were no significant variations on its quantity in
the biofilm matrices exposed to Vcz or Flu (Table 3).
Ultimately, the determination of the quantity of the
azole agents present in the biofilm matrix and the
consequent amount of drug capable of reaching the
cells confirmed that Vcz has the capacity to infiltrate
better the biofilm matrices than Flu (Table 4). As it is
known, Flu has a chemical structure distinct from
other antifungal drugs, providing a pharmacokinetic
profile highly differentiated with a molecular mass of
306.27 g/mol. The Vcz chemical structure, although
similar to Flu, presents a replacement of one triazole
group for a fluoropyrimidine and an introduction of a
methyl group and a molecular mass of 349.31 g/mol.
This univalent methyl group shows a stronger hy-
drophobic interaction with aromatic amino acids and
more extensive filling of the substrate-binding site
[30], making Vcz more absorbable (96%) than Flu
(90%) and with a better connection to the fungi cells,
thus emerging as a standard treatment for oropharyn-
geal or esophageal candidiasis [21]. This was in fact
substantiated in this work where C. glabrata biofilms
are much more susceptible to Vcz than to Flu
(Table 4).
Concluding, this study showed that the pattern of C.
glabrata’s biofilms susceptibilities to Vcz and its
comparative molecule, Flu, are effectively different.
As it is known, one of the possible mechanisms of
resistance to both agents is cell genetic alterations in
genes encoding for the ergosterol biosynthesis, which
seems to be also the key for the high levels of C.
glabrata biofilm azoles resistance, but this fact was
unable to completely explain the different resistance
profiles obtained for these two agents. Although there
were alterations in the matrix composition (proteins,
carbohydrates, including b-1,3 glucans, and ergos-
terol) in the presence of the azoles, there was
not found a direct correlation with Vcz efficacy.
Still, this study demonstrated that the diffusion of
the drugs within the biofilms is dependent on the azole
used, with Vcz having a better diffusion and an
enhanced activity against C. glabrata biofilms than
Flu, explaining, in part, its better performance and
efficacy for oral candidiasis.
This study also remarks that the tolerance or
resistance mechanisms to azoles are multifactorial
and cannot be linked to only one feature associated
specifically to the cells, the environment or the
ecosystems where they persist.
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